Diagnosis, Natural History, Management,tumor biology of Gastrinomas/PETs/Neuroendocrine tumors

胃泌素瘤是最常见的症状，恶性胰腺神经内分泌肿瘤（pNET）的患者有或没有MEN 1和足够数量的这些患者已经进入我们的方案，允许系统评估从一个广泛的数据库。此外，对于各种colloborator，这些信息通常与其他pNET/NET患者的信息相结合或进行比较。 今年完成了一些不同的研究以及各种合作指南/论文/研究，涉及分析胃泌素瘤和其他pNET/神经内分泌肿瘤管理中的主要临床问题。在这一年中，我们的前瞻性研究的信息被用来帮助制定两个欧洲神经内分泌肿瘤网络的立场文件，对pNET患者的未满足的需求，包括胃泌素瘤，以及其他NET与先进的疾病。制定pNET未满足需求的立场文件的ENERGY研究部分由詹森博士主持，并从NIH前瞻性数据库中获得了特别的输入。第二，与中国北京大学Y-J Chen教授合作的一项关于染色体3 p改变在胃泌素瘤中的潜在重要性的研究现已发表，与许多较小的研究相比，该研究表明该染色体区域与肿瘤或临床预后特征无关。 第三，与斯坦福大学的J. Norton教授、A. L. Titian博士及其同事合作进行的一项手术研究正处于提交的最后阶段，该研究涉及对局部晚期pNET手术结果的分析。最后，我们的前瞻性数据库中的数据与文献中的数据进行了比较，用于制定和确定pNET治疗中胰腺神经内分泌肿瘤患者总生存期和手术结局的预后因素。

Gastrinomas are the most common symptomatic, malignant pancreatic neuroendocrine tumor (pNETs) in patients with or without MEN1 and sufficient numbers of these patients have been entered into our protocols to allow systematic assessment from an extensive database. Furthermore, with various colloborators this information is often combined or compared to that in other pNET/NET patients. A number of different studies as well as various collaborative guidelines/papers/studies involved in the analyses of major clinical problems in the management of gastrinomas and other pNETs /neuroendocrine tumors were completed this year. During the year information from our prospective studies was used to help formulate two European Neuroendocrine Tumor Networks position papers on unmet needs in patients with pNETs including gastrinomas, as well as other NETs with advanced disease. The ENETs study section for formulating the unmet needs position paper for pNETs was chaired by Dr Jensen and had particular input from the NIH prospective database. Second, a collaborative study with Prof Y-J Chen, Peking University, Beijing China on the potential importance of alterations in chromosome 3p in gastrinomas is now published, which demonstrated , in contrast to a number of smaller studies, no correlation in this chromosomal area with tumor or clinical prognostic features. Third, a collaborative surgical study with Prof J. Norton, Dr A.L.Titian and their colleagues at Stanford University is in final stages of submission dealing with an analysis of results of surgery for locally advanced pNETs. Lastly, data from our prospective database compared with data from the literature was used in formulating and identifying prognostic factors on overall survival and surgical outcomes in patients with pancreatic neuroendocrine tumors in the management of pNETs.